561 related articles for article (PubMed ID: 33558665)
21. Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.
Jazayeri SB; Srivastava A; Shore N
Curr Opin Urol; 2022 May; 32(3):283-291. PubMed ID: 35552309
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
23. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
[TBL] [Abstract][Full Text] [Related]
24. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
25. Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer.
Chung DY; Ha JS; Cho KS
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34207755
[TBL] [Abstract][Full Text] [Related]
26. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
27. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
Shore N; Garcia-Horton V; Terasawa E; Ayyagari R; Grossman JP; Waldeck AR
Future Oncol; 2023 Feb; 19(5):385-395. PubMed ID: 36794575
[TBL] [Abstract][Full Text] [Related]
28. Non-metastatic castration-resistant prostate cancer: management recommendations.
Alcaraz Asensio A; Alvarez Ossorio JL; Cozar Olmo JM; Chantada Abal V; Juarez Soto A; Linares Espinos E; Moreno Jimenez J; Muñoz Rodriguez J; Perez Fentes D; Plata Bello A; Rodrigo Aliaga M; Unda Urzaiz M; Vilaseca A
Actas Urol Esp (Engl Ed); 2022 May; 46(4):193-213. PubMed ID: 35305957
[TBL] [Abstract][Full Text] [Related]
29. Using darolutamide in advanced prostate cancer: How I Do It.
Hamilton J
Can J Urol; 2021 Jun; 28(3):10673-10677. PubMed ID: 34129460
[TBL] [Abstract][Full Text] [Related]
30. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
31. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease.
Henriquez I; Spratt D; Gómez-Iturriaga A; Abuchaibe O; Couñago F
World J Clin Oncol; 2021 Jan; 12(1):6-12. PubMed ID: 33552935
[TBL] [Abstract][Full Text] [Related]
32. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
Hird AE; Magee DE; Bhindi B; Ye XY; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z; Wallis CJD
Clin Genitourin Cancer; 2020 Oct; 18(5):343-350. PubMed ID: 32278840
[TBL] [Abstract][Full Text] [Related]
33. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis].
Hadaschik B; Hellmis E
Urologe A; 2021 Jun; 60(6):753-759. PubMed ID: 33575824
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
36. Management of nonmetastatic castration-resistant prostate cancer.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):366-371. PubMed ID: 30015690
[TBL] [Abstract][Full Text] [Related]
37. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Rettig MB; Beltran H; Oh WK
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):1-20. PubMed ID: 35579577
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract][Full Text] [Related]
39. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective.
Ingrosso G; Bottero M; Becherini C; Caini S; Alì E; Lancia A; Ost P; Sanguineti G; Siva S; Zilli T; Francolini G; Bellavita R; Aristei C; Livi L; Detti B
Semin Oncol; 2022 Oct; 49(5):409-418. PubMed ID: 36192243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
